The Panther Fusion GBS assay is a real-time PCR assay to detect the gram-positive bacterium Streptococcus agalactiae (GBS) from antepartum women. It features world-class performance and sensitivity so providers can diagnose GBS confidently and take steps to reduce transmission to babies.1

When transmitted to babies during childbirth, GBS can lead to sepsis, pneumonia, meningitis and death.2 If GBS is diagnosed before birth, providers may administer antibiotic prophylaxis during delivery, which can reduce the chance of transmission. By using tests with excellent sensitivity and performance like the Panther Fusion GBS assay, providers can focus on providing the best-possible care.

The Panther Fusion GBS assay leverages the benefits of the Panther Fusion® system and growing menu of Aptima® and Panther Fusion® assays.

High assay sensitivity supports better patient care

Unit-dose lyophilized reagents help eliminate reagent waste and the need for manual reagent preparation.

Ready-to-use, unit-dose format with 60-day onboard stability helps reduce waste.

Run alone or simultaneously with other Panther Fusion or Aptima assays, without batching restrictions.

The Panther Fusion GBS assay is a real-time PCR assay for the qualitative detection of GBS in antepartum women with dual-target detection of Cfb and SIP genes.  This assay is compatible with vaginal-rectal swab samples enriched in LIM and Carrot broth.

This assay leverages the benefits of the Panther Fusion system, with flexible workflow, improved laboratory efficiency and superior performance and automation.1,3-7